Lilly Xigris Add-On Medicare Payment Decision Awaits Further CMS Analysis
Executive Summary
The Centers for Medicare & Medicaid Services may consider providing add-on Medicare payments for Lilly's sepsis agent Xigris for a narrower patient population than FDA's approved indication